bioAffinity Technologies, Inc.今日宣布，公司已成功获得香港专利授权，该专利覆盖其创新的Cypath® Lung非侵入性肺癌诊断技术。此项专利的授予标志着公司在全球范围内保护其核心诊断技术知识产权方面迈出了重要一步，也为其在亚洲市场的进一步拓展奠定了坚实的基础。
Cypath® Lung作为一种突破性的非侵入性检测手段，旨在通过分析患者痰液样本中的细胞特征，实现对肺癌的早期筛查与诊断。与传统侵入性检测方法相比，该技术不仅降低了患者的痛苦与风险，还显著提升了检测的可及性与便利性。
公司管理层表示，香港作为国际金融与科技创新中心，其专利体系的认可不仅是对Cypath® Lung技术先进性的权威肯定，更是公司全球知识产权战略布局中的关键一环。这一进展有望加速该技术在香港及更广泛亚太地区的临床应用与商业化进程，为肺癌早筛领域带来新的变革。
随着全球对精准医疗和早期诊断需求的持续攀升，bioAffinity Technologies正凭借其差异化的技术优势，逐步构建起覆盖多区域的知识产权保护网络，旨在为全球患者提供更为高效、安全且精准的肺癌诊断解决方案。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.